|4Aug 25, 7:31 PM ET

Chhabra Meenu 4

4 · Apexigen, Inc. · Filed Aug 25, 2023

Insider Transaction Report

Form 4
Period: 2023-08-23
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    2023-08-23100,0000 total
    Exercise: $2.65Exp: 2032-09-29Common Stock (100,000 underlying)
Footnotes (1)
  • [F1]The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023, by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION